Click for best price
Immune Thrombocytopenia Drugs Market Size, Share 2023
Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.
This report aims to provide a comprehensive presentation of the global market for Immune Thrombocytopenia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Thrombocytopenia Drugs. This report contains market size and forecasts of Immune Thrombocytopenia Drugs in global, including the following market information:
The global Immune Thrombocytopenia Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.
We surveyed the Immune Thrombocytopenia Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Immune Thrombocytopenia Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Immune Thrombocytopenia Drugs Market Segment Percentages, by Type, 2022 (%)
- Thrombopoietin Receptor Agonists (TPO-RAs)
- Corticosteroids
- Intravenous Immunoglobins (IVIGs)
- Other Drugs
Global Immune Thrombocytopenia Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Immune Thrombocytopenia Drugs Market Segment Percentages, by Application, 2022 (%)
- Biotechnology and Pharmaceutical Companies
- Hospitals and Diagnostic Centers
- Academic Institutes and Research Organizations
Global Immune Thrombocytopenia Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Immune Thrombocytopenia Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Immune Thrombocytopenia Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Immune Thrombocytopenia Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
- Rigel Pharmaceuticals Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Immune Thrombocytopenia Drugs, market overview.
Chapter 2: Global Immune Thrombocytopenia Drugs market size in revenue.
Chapter 3: Detailed analysis of Immune Thrombocytopenia Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Immune Thrombocytopenia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Immune Thrombocytopenia Drugs Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
69 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Immune Thrombocytopenia Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Immune Thrombocytopenia Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Immune Thrombocytopenia Drugs Overall Market Size
2.1 Global Immune Thrombocytopenia Drugs Market Size: 2022 VS 2030
2.2 Global Immune Thrombocytopenia Drugs Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Immune Thrombocytopenia Drugs Players in Global Market
3.2 Top Global Immune Thrombocytopenia Drugs Companies Ranked by Revenue
3.3 Global Immune Thrombocytopenia Drugs Revenue by Companies
3.4 Top 3 and Top 5 Immune Thrombocytopenia Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Immune Thrombocytopenia Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Immune Thrombocytopenia Drugs Players in Global Market
3.6.1 List of Global Tier 1 Immune Thrombocytopenia Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Immune Thrombocytopenia Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Immune Thrombocytopenia Drugs Market Size Markets, 2022 & 2030
4.1.2 Thrombopoietin Receptor Agonists (TPO-RAs)
4.1.3 Corticosteroids
4.1.4 Intravenous Immunoglobins (IVIGs)
4.1.5 Other Drugs
4.2 By Type - Global Immune Thrombocytopenia Drugs Revenue & Forecasts
4.2.1 By Type - Global Immune Thrombocytopenia Drugs Revenue, 2018-2023
4.2.2 By Type - Global Immune Thrombocytopenia Drugs Revenue, 2024-2030
4.2.3 By Type - Global Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Immune Thrombocytopenia Drugs Market Size, 2022 & 2030
5.1.2 Biotechnology and Pharmaceutical Companies
5.1.3 Hospitals and Diagnostic Centers
5.1.4 Academic Institutes and Research Organizations
5.2 By Application - Global Immune Thrombocytopenia Drugs Revenue & Forecasts
5.2.1 By Application - Global Immune Thrombocytopenia Drugs Revenue, 2018-2023
5.2.2 By Application - Global Immune Thrombocytopenia Drugs Revenue, 2024-2030
5.2.3 By Application - Global Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Immune Thrombocytopenia Drugs Market Size, 2022 & 2030
6.2 By Region - Global Immune Thrombocytopenia Drugs Revenue & Forecasts
6.2.1 By Region - Global Immune Thrombocytopenia Drugs Revenue, 2018-2023
6.2.2 By Region - Global Immune Thrombocytopenia Drugs Revenue, 2024-2030
6.2.3 By Region - Global Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Immune Thrombocytopenia Drugs Revenue, 2018-2030
6.3.2 US Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.3.3 Canada Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.3.4 Mexico Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Immune Thrombocytopenia Drugs Revenue, 2018-2030
6.4.2 Germany Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.4.3 France Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.4.4 U.K. Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.4.5 Italy Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.4.6 Russia Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.4.7 Nordic Countries Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.4.8 Benelux Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Immune Thrombocytopenia Drugs Revenue, 2018-2030
6.5.2 China Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.5.3 Japan Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.5.4 South Korea Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.5.5 Southeast Asia Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.5.6 India Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Immune Thrombocytopenia Drugs Revenue, 2018-2030
6.6.2 Brazil Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.6.3 Argentina Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Immune Thrombocytopenia Drugs Revenue, 2018-2030
6.7.2 Turkey Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.7.3 Israel Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.7.4 Saudi Arabia Immune Thrombocytopenia Drugs Market Size, 2018-2030
6.7.5 UAE Immune Thrombocytopenia Drugs Market Size, 2018-2030
7 Immune Thrombocytopenia Drugs Companies Profiles
7.1 Amgen Inc.
7.1.1 Amgen Inc. Company Summary
7.1.2 Amgen Inc. Business Overview
7.1.3 Amgen Inc. Immune Thrombocytopenia Drugs Major Product Offerings
7.1.4 Amgen Inc. Immune Thrombocytopenia Drugs Revenue in Global Market (2018-2023)
7.1.5 Amgen Inc. Key News & Latest Developments
7.2 CSL Ltd.
7.2.1 CSL Ltd. Company Summary
7.2.2 CSL Ltd. Business Overview
7.2.3 CSL Ltd. Immune Thrombocytopenia Drugs Major Product Offerings
7.2.4 CSL Ltd. Immune Thrombocytopenia Drugs Revenue in Global Market (2018-2023)
7.2.5 CSL Ltd. Key News & Latest Developments
7.3 Horizon Therapeutics Plc
7.3.1 Horizon Therapeutics Plc Company Summary
7.3.2 Horizon Therapeutics Plc Business Overview
7.3.3 Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Major Product Offerings
7.3.4 Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Revenue in Global Market (2018-2023)
7.3.5 Horizon Therapeutics Plc Key News & Latest Developments
7.4 Merck & Co., Inc.
7.4.1 Merck & Co., Inc. Company Summary
7.4.2 Merck & Co., Inc. Business Overview
7.4.3 Merck & Co., Inc. Immune Thrombocytopenia Drugs Major Product Offerings
7.4.4 Merck & Co., Inc. Immune Thrombocytopenia Drugs Revenue in Global Market (2018-2023)
7.4.5 Merck & Co., Inc. Key News & Latest Developments
7.5 Novartis AG
7.5.1 Novartis AG Company Summary
7.5.2 Novartis AG Business Overview
7.5.3 Novartis AG Immune Thrombocytopenia Drugs Major Product Offerings
7.5.4 Novartis AG Immune Thrombocytopenia Drugs Revenue in Global Market (2018-2023)
7.5.5 Novartis AG Key News & Latest Developments
7.6 Rigel Pharmaceuticals Inc.
7.6.1 Rigel Pharmaceuticals Inc. Company Summary
7.6.2 Rigel Pharmaceuticals Inc. Business Overview
7.6.3 Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Major Product Offerings
7.6.4 Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Revenue in Global Market (2018-2023)
7.6.5 Rigel Pharmaceuticals Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Immune Thrombocytopenia Drugs Market Opportunities & Trends in Global Market
Table 2. Immune Thrombocytopenia Drugs Market Drivers in Global Market
Table 3. Immune Thrombocytopenia Drugs Market Restraints in Global Market
Table 4. Key Players of Immune Thrombocytopenia Drugs in Global Market
Table 5. Top Immune Thrombocytopenia Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Immune Thrombocytopenia Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Immune Thrombocytopenia Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Immune Thrombocytopenia Drugs Product Type
Table 9. List of Global Tier 1 Immune Thrombocytopenia Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Immune Thrombocytopenia Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Immune Thrombocytopenia Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Immune Thrombocytopenia Drugs Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Immune Thrombocytopenia Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Immune Thrombocytopenia Drugs Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Immune Thrombocytopenia Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Immune Thrombocytopenia Drugs Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2024-2030
Table 30. Amgen Inc. Company Summary
Table 31. Amgen Inc. Immune Thrombocytopenia Drugs Product Offerings
Table 32. Amgen Inc. Immune Thrombocytopenia Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Amgen Inc. Key News & Latest Developments
Table 34. CSL Ltd. Company Summary
Table 35. CSL Ltd. Immune Thrombocytopenia Drugs Product Offerings
Table 36. CSL Ltd. Immune Thrombocytopenia Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. CSL Ltd. Key News & Latest Developments
Table 38. Horizon Therapeutics Plc Company Summary
Table 39. Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Product Offerings
Table 40. Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Horizon Therapeutics Plc Key News & Latest Developments
Table 42. Merck & Co., Inc. Company Summary
Table 43. Merck & Co., Inc. Immune Thrombocytopenia Drugs Product Offerings
Table 44. Merck & Co., Inc. Immune Thrombocytopenia Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Merck & Co., Inc. Key News & Latest Developments
Table 46. Novartis AG Company Summary
Table 47. Novartis AG Immune Thrombocytopenia Drugs Product Offerings
Table 48. Novartis AG Immune Thrombocytopenia Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Novartis AG Key News & Latest Developments
Table 50. Rigel Pharmaceuticals Inc. Company Summary
Table 51. Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Product Offerings
Table 52. Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Rigel Pharmaceuticals Inc. Key News & Latest Developments
List of Figures
Figure 1. Immune Thrombocytopenia Drugs Segment by Type in 2022
Figure 2. Immune Thrombocytopenia Drugs Segment by Application in 2022
Figure 3. Global Immune Thrombocytopenia Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Immune Thrombocytopenia Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Immune Thrombocytopenia Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Immune Thrombocytopenia Drugs Revenue in 2022
Figure 8. By Type - Global Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
Figure 9. By Application - Global Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
Figure 10. By Type - Global Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
Figure 12. By Application - Global Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
Figure 14. By Region - Global Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
Figure 15. By Country - North America Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
Figure 16. US Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
Figure 20. Germany Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 21. France Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
Figure 28. China Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. India Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
Figure 34. Brazil Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Immune Thrombocytopenia Drugs Revenue Market Share, 2018-2030
Figure 37. Turkey Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Immune Thrombocytopenia Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. Amgen Inc. Immune Thrombocytopenia Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. CSL Ltd. Immune Thrombocytopenia Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Merck & Co., Inc. Immune Thrombocytopenia Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Novartis AG Immune Thrombocytopenia Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
